New RA drug JADE201 enters first human safety trial

NCT ID NCT07533955

Recruiting now Disease control Sponsor: Jade Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a single injection of JADE201 in 36 adults with rheumatoid arthritis. The main goal is to check safety and how the body processes the drug. Participants receive either JADE201 or a placebo, and researchers monitor side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JADE201
What this could lead to: If safe and effective, JADE201 could become a new treatment option to control rheumatoid arthritis symptoms and inflammation.
What could go wrong: This is a very early Phase 1 trial with only 36 people. The main goal is safety, not effectiveness. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEMATOID ARTHRITIS

Contacts and locations

Locations

Jade Clinical Site
RECRUITING

Chisinau, Moldova, 2025, Moldova
Jade Clinical Site
RECRUITING

Ivano-Frankivsk, Ukraine, 76018, Ukraine
Jade Clinical Site
RECRUITING

Kyiv, Ukraine, 02000, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.